» Articles » PMID: 36443699

Risk Factors for Severe Covid-19 Breakthrough Infections: an Observational Longitudinal Study

Abstract

Background: The drive to vaccinate large populations is nowadays the main instrument for combating the pandemic and preventing serious disease and death. However, breakthrough infection (post-vaccination infection) still happens after vaccination among fully vaccinated people. We aimed to assess the severity outcomes and to determine its associated factors among vaccinated COVID-19 cases in the governorate of Sousse, Tunisia.

Methods: We carried out a five-month observational longitudinal study including all the population of Sousse. Confirmed infections of SARS-CoV-2 and the vaccination status are recorded in the daily COVID- 19 database of the Regional Office of the Tunisian Ministry of Health. We included all post-vaccination COVID-19 cases for the analysis of the COVID-19 serious outcomes. Data were collected via 15-min telephonic call interviews conducted by trained interviewers. Descriptive analysis with calculating incidence rates of confirmed COVID-19 cases per 100,000 inhabitants was conducted. In binary logistic regression, adjusted odds ratios along with 95% intervals confidence were performed to determine factors related to severe or critical COVID-19.

Results: As of 31 July 2021, 107,545 persons over 19 years old have received at least one dose of COVID-19 vaccination. Among the vaccinated population, we traced and included 765 breakthrough infection cases, and the incidence rate was 711.3 per week. The majority were female (sex-ratio = 0.8), and the average age of the overall cases was 55.7 years. The prevalence of severe or critical cases in vaccinated COVID-19 patients occurs in 10.8% of cases. Patients with a medical history of cardiovascular diseases had more than two times increased odds to have a severe or critical disease. We also found the highest self-estimation of adherence to preventive measures was inversely correlated to serious cases and having an incomplete vaccination schema was strongly associated with complications.

Conclusions: We tried to provide evidence about the breakthrough infections to improve measures of prevention and control of COVID-19. Boosting immunity for vulnerable patients added to maintaining and promoting preventive measures are not only essential to prevent severe cases of breakthrough infections of COVID-19, but also other influenza-like diseases.

Citing Articles

Hesitancy towards COVID-19 booster vaccine among healthcare workers in Bangladesh.

Shoshi H, Basher A, Pyash A, Hossain M, Chowdhury F, Hassan M BMC Health Serv Res. 2025; 25(1):346.

PMID: 40050921 PMC: 11884019. DOI: 10.1186/s12913-025-12482-6.


Impact of pharmaceutical and non-pharmaceutical interventions on COVID-19 in Tunisia.

Abroug H, Bennasrallah C, Ben Fredj M, Kacem M, Ben Belgacem M, Dhouib W BMC Public Health. 2024; 24(1):2803.

PMID: 39396980 PMC: 11472591. DOI: 10.1186/s12889-024-19236-9.


SARS-CoV-2 Evolution: Immune Dynamics, Omicron Specificity, and Predictive Modeling in Vaccinated Populations.

Zhang X, Li M, Zhang N, Li Y, Teng F, Li Y Adv Sci (Weinh). 2024; 11(40):e2402639.

PMID: 39206813 PMC: 11516136. DOI: 10.1002/advs.202402639.


SARS-CoV-2 vaccine breakthrough infection and the evaluation of safety precaution practice before and after vaccination among healthcare workers in South West, Nigeria.

Oni O, Osho P, Odesanmi T, Raji H, Oluranti F, Ibina D BMC Public Health. 2024; 24(1):1259.

PMID: 38720278 PMC: 11077696. DOI: 10.1186/s12889-024-18663-y.


Natural Killer Cells Do Not Attenuate a Mouse-Adapted SARS-CoV-2-Induced Disease in Mice.

Ellsworth C, Wang C, Katz A, Chen Z, Islamuddin M, Yang H Viruses. 2024; 16(4).

PMID: 38675952 PMC: 11054502. DOI: 10.3390/v16040611.


References
1.
Jaen R, Val-Blasco A, Prieto P, Gil-Fernandez M, Smani T, Lopez-Sendon J . Innate Immune Receptors, Key Actors in Cardiovascular Diseases. JACC Basic Transl Sci. 2020; 5(7):735-749. PMC: 7393405. DOI: 10.1016/j.jacbts.2020.03.015. View

2.
Brunelli S, Sibbel S, Karpinski S, Marlowe G, Walker A, Giullian J . Comparative Effectiveness of mRNA-based BNT162b2 Vaccine versus Adenovirus Vector-Based Ad26.COV2.S Vaccine for the Prevention of COVID-19 among Dialysis Patients. J Am Soc Nephrol. 2022; 33(4):688-697. PMC: 8970445. DOI: 10.1681/ASN.2021101395. View

3.
Lipsitch M, Krammer F, Regev-Yochay G, Lustig Y, Balicer R . SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact. Nat Rev Immunol. 2021; 22(1):57-65. PMC: 8649989. DOI: 10.1038/s41577-021-00662-4. View

4.
Paltiel A, Schwartz J, Zheng A, Walensky R . Clinical Outcomes Of A COVID-19 Vaccine: Implementation Over Efficacy. Health Aff (Millwood). 2020; 40(1):42-52. PMC: 7931245. DOI: 10.1377/hlthaff.2020.02054. View

5.
Chouikha A, Fares W, Laamari A, Haddad-Boubaker S, Belaiba Z, Ghedira K . Molecular Epidemiology of SARS-CoV-2 in Tunisia (North Africa) through Several Successive Waves of COVID-19. Viruses. 2022; 14(3). PMC: 8956073. DOI: 10.3390/v14030624. View